Atsena Therapeutics
Manufacturing · North Carolina, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
8 Davis Dr Ste 300, Durham, North Caroli...Phone Number
(984) 261-2001Website
www.atsenatx.comRevenue
$7.6 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Atsena Therapeutics
Based out of Durham, N.C., Atsena Therapeutics is a clinical-stage gene therapy with a focus on blindness prevention.Explore more
Atsena Therapeutics Org Chart
Get the full picture
Sign in to uncover key details.
PO
Vice President, Clinical Operations
SM
Vice President, Medical Affairs
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Atsena Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Atsena Therapeutics recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Atsena Therapeutics had a recent Job posting/layoffs
Check out if Atsena Therapeutics is spiking on competitors!
Funding: Get notified immidiatlly once Atsena Therapeutics has new funding data
Check if Atsena Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Atsena Therapeutics launches new products
Congratulate Masked Content for being promoted to Masked Content at Atsena Therapeutics
Atsena Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Recommended Actions
Find VP level buyers at Atsena Therapeutics
Find 2 more new buyers
Compare Similar Companies to Atsena Therapeutics
Compare insights from companies similar to Atsena Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Atsena Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Atsena Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Atsena Therapeutics.
Atsena Therapeutics financials insights
Gather financial insights about Atsena Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Series A
$55M
2023
Other Financing Round
$24.5M
2025
Series C
$150M
Atsena Therapeutics Tech Stack
A closer look at the technologies used by Atsena Therapeutics
Most Recent Scoops
Hiring Plans
Atsena Therapeutics has more open roles in Operations than it has had at any time in the past 12 months. Technologies mentioned include: Remote.
Hiring Plans
Person-Based
Pharmaceuticals
Open Position
Project
Laboratory Operations, Medical Research, Clinical Operations
New Hire
Executive Move
Executive Moves, New Hire
Atsena Therapeutics News & Media
Atsena Therapeutics Receives Orphan Designation from the European Medicines Agency (EMA) for ATSN-101 and ATSN-201
Orphan designation provides market exclusivity and development benefits in the European Union as both programs advance in global pivotal clinical trialsAtsena Therapeutics Selects ATSN-401 Clinical Candidate, a Potential Best-in-Class Gene Therapy for Stargardt Disease
Proprietary dual-vector platform delivers full-length ABCA4, enabled by Atsena's laterally spreading AAV.SPR capsid for delivery to the central retina without foveal detachmentAtsena Therapeutics Doses First Patient and Reports Rapid Early Enrollment in Pivotal Trial of ATSN-201 for X-Linked Retinoschisis
Enrollment expected to complete Q1 2027; topline results anticipated 1H 2028; BLA filing targeted for 2H 2028Atsena Presents Positive Clinical Data from Its XLRS and LCA1 Gene Therapy Programs at ARVO 2026
12-month results from Part A of LIGHTHOUSE Trial reinforce ATSN-201's favorable safety profile and durable structural and functional benefits in patients with X-linked retinoschisis
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Atsena Therapeutics
Sign Up For FreeTo access detailed company insights
Based out of Durham, N.C., Atsena Therapeutics is a clinical-stage gene therapy with a focus on blindness prevention.... Read More
